Clinical Evidence & Research

This randomized controlled clinical trial evaluated the efficacy of Wharton’s Jelly MSC-derived exosomes in accelerating diabetic foot ulcer healing. The study demonstrated significant improvements in wound closure rates and tissue regeneration compared to standard care.

A comprehensive review examining the achievements and ongoing challenges in using Wharton’s Jelly mesenchymal stem cells for diabetes management. The authors synthesize evidence across multiple studies to assess clinical viability and therapeutic mechanisms.

A non-randomized, open-label, multi-center clinical trial protocol assessing the safety and efficacy of umbilical cord-derived Wharton’s Jelly stem cells for knee osteoarthritis treatment. The protocol outlines outcome measures for pain reduction and functional improvement.

This clinical research study evaluated the efficacy and safety of Wharton’s Jelly-derived exosomes in patients with traumatic brain injury. Findings support the neuroprotective and regenerative potential of WJ-MSC exosome therapy in acute TBI settings.

A comprehensive overview of the therapeutic mechanisms underlying stem cell applications in regenerative medicine. This chapter synthesizes current understanding of how stem cells promote tissue repair, immune modulation, and paracrine signaling across multiple conditions.

A peer-reviewed research article examining stem cell applications in neurological conditions and brain injury treatment. The study explores cellular and molecular mechanisms by which stem cell therapies may restore function in patients with brain pathology.

This research article investigates the pharmacological mechanisms of stem cell-derived therapeutics, with a focus on paracrine signaling, exosome-mediated delivery, and the regulatory pathways that govern regenerative outcomes in clinical applications.

This systematic review evaluates the therapeutic potential of MSC-derived exosomes in inflammatory and autoimmune conditions. The authors document how exosomal cargo — including miRNAs, cytokines, and growth factors — mediates immunosuppression, reduces inflammatory cytokine production, and promotes tissue homeostasis across a range of disease models.

A clinical review assessing the immunomodulatory properties and safety profile of umbilical cord-derived mesenchymal stem cells across multiple clinical applications. The study confirms low immunogenicity, strong paracrine activity, and an absence of serious adverse events across reviewed trials, supporting the use of UC-MSCs as an off-the-shelf allogeneic therapy.

This article reviews the role of MSC-derived exosomes in neurodegenerative disease, with emphasis on their ability to cross the blood-brain barrier, deliver neuroprotective cargo, and modulate microglial activation. The authors highlight promising preclinical and early clinical findings in Alzheimer’s disease, Parkinson’s disease, and ALS models.

A clinical study reporting safety and efficacy outcomes following Wharton’s Jelly MSC administration in patients with autoimmune and chronic inflammatory conditions. Results demonstrated significant reductions in inflammatory biomarkers (CRP, IL-6, TNF-α), improved quality of life scores, and no serious treatment-related adverse events over the follow-up period.

This systematic review synthesizes evidence on MSC-derived exosome efficacy in tissue repair across wound healing, bone regeneration, and cartilage repair models. Key findings include accelerated closure of chronic wounds, enhanced osteogenic differentiation, and reduced cartilage degradation — driven primarily by exosomal miRNA and growth factor delivery.

A foundational review article examining the paracrine mechanisms by which mesenchymal stem cells exert their therapeutic effects — independent of direct cell engraftment. The authors detail how secreted factors including VEGF, HGF, IGF-1, and exosomal miRNAs drive angiogenesis, anti-apoptosis, immunomodulation, and tissue remodeling across cardiac, renal, and musculoskeletal models.

This study examines the paracrine secretion properties and immune system modulation capabilities of mesenchymal stem cells, supporting their potential as a promising candidate for treating autism spectrum disorders (ASDs). Findings align with observed improvements in neuroinflammatory markers in ASD patients.

Investigates the therapeutic application of MSC-derived exosomes as a cell-free intervention for autism spectrum disorder. The study explores exosome-mediated mechanisms including neuroinflammation modulation, neural circuit repair, and blood-brain barrier penetration relevant to ASD treatment.